Previous close | 3.4350 |
Open | 3.4003 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 3.4003 - 3.4400 |
52-week range | 2.6300 - 4.0400 |
Volume | |
Avg. volume | 28,665 |
Market cap | 10.291B |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | 12.74 |
EPS (TTM) | 0.2700 |
Earnings date | 23 May 2024 - 27 May 2024 |
Forward dividend & yield | 0.14 (4.16%) |
Ex-dividend date | 03 June 2024 |
1y target est | N/A |
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Cli